Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNBELIEVABLE: Roche - The Untold Story

Lineage Cell Therapeutics Q1 Earnings Call Highlights

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) reported first-quarter 2026 results and used its earnings call to highlight progress across its cell therapy pipeline, including its lead OpRegen program in geographic atrophy, a newly launched corneal endothelial cell program called COR1, and ongoing ma

MarketBeat

Roche gets European approval for Alzheimer’s diagnosis blood test

Swiss pharmaceutical company Roche has received European approval for a blood test that can detect and rule out Alzheimer’s disease, offering a simpler and less invasive alternative to current diagnostic methods.

Euronews

Halozyme Therapeutics Q1 Earnings Call Highlights

Halozyme Therapeutics (NASDAQ:HALO) reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and announced a new $1 billion share repurchase authorization. On the company’s earnings call, President and CEO

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

US Drug Pricing Deal May Lead to Swiss Medicine Price Hikes

US drug price cuts may push up the cost of new medicines in Switzerland, Roche's CEO warns.

International Business Times

Cancer Focused Olema Pharmaceuticals Stock Soars 150% - Here's Why

Olema Pharmaceuticals Inc. (NASDAQ:OLMA) stock is trading higher on Tuesday, with a session volume of 45.12 million compared to the average volume of 1.171 million as per data from Benzinga Pro.

Benzinga

Simple blood test gets green light by FDA to improve early detection of Alzheimer’s disease

Millions of Americans are living with Alzheimer’s and hundreds of thousands are diagnosed each year

The Independent UK

Trump’s latest tariff threat raises concerns for UK pharmaceuticals

Britain will ‘actively engage’ with US over possible 100% duties, with truck and cabinet makers also in firing line

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

Roche Targets Top Spot In Weight Loss Drug Market

Roche Holdings AG (OTC:RHHBY) on Monday outlined its plan to become a leading player in the surging weight-loss drug market, pushing its obesity pipeline farther into late-stage development as it eyes competition with Eli Lilly And Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO).

Benzinga

Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push

On Thursday, Roche Holdings AG (OTC:RHHBY) agreed to acquire 89bio, Inc. (NASDAQ:ETNB) for $2.4 billion. 89Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for liver and cardiometabolic diseases.

Benzinga

‘Game-changing’ new Alzheimer’s drug could slow progression of disease

There are currently estimated to be 982,000 people with some form of dementia, including Alzheimer's in the UK

The Independent UK

New antibiotic that could save millions of lives enters final testing

IN FULL

The Independent UK

New ‘superbug’ antibiotic to treat sepsis and pneumonia enters last phase of testing

It is hoped that the drug zosurabalpin will be approved by the end of the decade

The Independent UK

3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.

See these three top-10 stocks in the pharmaceutical industry that are pledging investment in the United States totalling over $100 billion.

MarketBeat

US drug firm Merck says existing Trump tariffs will cost it $200m this year

Company’s forecast does not account for threatened ‘major’ tariff that could also be levied on pharmaceutical imports

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

Euronews

Swiss pharma giant Roche pledges to invest €47 billion in the US

The investment plans include new R&D sites in four US states and creating more than 12,000 jobs, according to the Swiss pharmaceutical company.

Latin Times

Roche Says Will Invest $50 Bn In US, As Tariff War Uncertainty Swells

Trump's administration is blowing hot and cold on pharmaceutical products, which initially benefited from exemptions in the round of tariffs announced on April 2.

Fortune

Swiss drugmaker Roche leans into Trump tariff formula with $50bn promise to invest in U.S.

Roche promised that its investments in the U.S. means it will export more medicines than it imports in the U.S.

The Guardian - UK

Swiss drugmaker Roche to invest $50bn in US in effort to dodge Trump tariffs

Company says it will create 12,000 jobs in manufacturing and R&D over next five years

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times

Roche Says Will Invest $50 Bn In US Over Next Five Years

The firm already has plants in the United States, and said the move would help expand capacity at sites in Kentucky, Indiana, New Jersey, Oregon and California.

Fortune

Bayer CEO Bill Anderson on diversity initiatives, new menopause drugs and taming a runaway bureaucracy

Bayer's teams run on 90-day cycles, so the clock is always ticking on delivering on their goals.

inkl

How Healthcare Leader Clara Latorre is Transforming Dermatology and Oncology Through Strategic Innovation

In today’s fast-paced healthcare world, few leaders balance clinical expertise and strategic innovation as seamlessly as Dr. Clara Latorre.

Benzinga

Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details

Roche agrees to acquire Poseida Therapeutics for $1.5 billion, expanding its CAR-T therapy platform with a focus on hematologic malignancies and solid tumors.

Benzinga

Why Poseida Therapeutics Shares Are Trading Higher By 219%; Here Are 20 Stocks Moving Premarket

Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) rose sharply in today's pre-market trading after the company agreed to be acquired by Roche in a $1.5 billion deal.

Evening Standard

Blood test could ‘reliably rule out’ Alzheimer’s, trial finds

There are hopes it will offer reassurance to patients with cognitive decline and help them avoid unnecessary further testing, researchers said.

The Conversation

Pharma company funding for patient advocacy groups needs to be transparent

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.